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The application of transcription factor activated luciferase reporter cassettes in vitro is widespread 
but potential for in vivo application has not yet been realized. Bioluminescence imaging enables non-
invasive tracking of gene expression in transfected tissues of living rodents. However the mature 
immune response limits luciferase expression when delivered in adulthood. We present a novel 
approach of tissue-targeted delivery of transcription factor activated luciferase reporter lentiviruses 
to neonatal rodents as an alternative to the existing technology of generating germline transgenic 
light producing rodents. At this age, neonates acquire immune tolerance to the conditionally 
responsive luciferase reporter. This simple and transferrable procedure permits surrogate quantitation 
of transcription factor activity over the lifetime of the animal. We show principal efficacy by 
temporally quantifying NFκB activity in the brain, liver and lungs of somatotransgenic reporter mice 
subjected to lipopolysaccharide (LPS)-induced inflammation. This response is ablated in Tlr4−/− mice 
or when co-administered with the anti-inflammatory glucocorticoid analogue dexamethasone. 
Furthermore, we show the malleability of this technology by quantifying NFκB-mediated luciferase 
expression in outbred rats. Finally, we use somatotransgenic bioimaging to longitudinally quantify 
LPS- and ActivinA-induced upregulation of liver specific glucocorticoid receptor and Smad2/3 reporter 
constructs in somatotransgenic mice, respectively.
Luciferase enzymes catalyze their substrates in a reaction that produces light; a reliable surrogate for 
relative protein expression. The application of luciferase as a reporter gene has been widely exploited in 
the study of promoter activity in vitro1 but its use in vivo has largely been restricted to evaluating gene 
delivery and marking engrafted cells2. The use of transcription factor (TF) activated reporter constructs 
whereby serial TF binding consensus sequences are engineered upstream of a minimal promoter driving 
luciferase is established. Such approaches have been used to define and quantify nuclear translocation 
and DNA binding of TF complexes to conditionally activate or repress gene expression. This approach 
has resulted in the definition of minimal DNA binding consensus sequences for the majority of charac-
terized TFs. Such cellular responses to disease agonists are well studied in monolayer cultures in vitro 
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but temporal tissue-specific studies hold far greater relevance to the understanding and treatment of dis-
ease. To interrogate disease progression at the molecular level it is necessary to study reliable biomarker 
activity in living animals over time but biomarkers are most often limited to blood and urine sampling.
The emergence of bioluminescence imaging (BLI) has enabled the use of promoter activated sur-
rogate luciferase transgene activity as a biomarker in living small animals2–4. Photonic emissions from 
luciferase activity in the visceral organs of rats or mice can now be simply and accurately detected 
using comparatively inexpensive charge-coupled device (CCD) cameras. There has been some success 
in utilizing germline light producing transgenic (LPT) mice where luciferase is engineered downstream 
of endogenous gene promoters or a TF-activated construct inserted into a genomic “safe harbor” site. 
The advantage of this technology is that every cell contains a copy of the genetic biosensor therefore 
an accurate whole-body representation of the activity of any promoter/enhancer cassette is provided. 
However, this clonal ubiquity severely impedes bioluminescent monitoring of transcriptional activity in 
individual organs or tissues since the signal is difficult to resolve from “background noise” of adjacent 
tissues. Moreover, these transgenic strains are often developed and maintained on a limited number of 
genetic backgrounds, and therefore backcrossing is frequently necessary leading to increased costs and 
significant time delays.
Gene transfer of such TF activated reporters to adult rodents has been shown to result in loss of 
transduced cells through cellular immune responses5. Some success has been achieved by employment 
of immune-deficient mice1 however this complicates the study of TF activity in established transgenic 
or biological disease models where immune competency is required. We have discovered that lentivi-
rus vector administration to neonatal rodents, before full maturation of the immune system, leads to 
immune tolerance to luciferase and permits lifelong transgene expression6. In addition, selection of the 
appropriate injection route and lentivirus pseudotype confers organ and tissue selectivity. To enable 
tissue-specific measurement of the activity of virtually any TF we have generated a parental lentivirus 
construct to shuttle serial TF consensus binding sequences upstream of an in vivo optimized firefly lucif-
erase (FLuc)/eGFP expression cassette. High-titer lentivirus is targeted to tissues using a combination 
of route administration and viral pseudotyping in newborn neonates. This achieves substantially greater 
organ spread than in adults and induces immune tolerance to the transgenic proteins, thus permitting 
lifelong conditional expression. Experimentation on these somatotransgenic animals is quick, taking less 
than 2 months from selection of TF to data acquisition, is cost effective in comparison to LPT produc-
tion/colony maintenance and crucially is tissue-specific.
We have developed this methodology as a platform to study TF activity during disease pathogenesis 
or for pre-clinical evaluations of drug efficacy. We present data showing the utility of this approach 
by modeling NFκ B activity in living mice and rats in response to pro-inflammatory challenge. Early 
inflammatory responses are mediated through NFκ B signaling in most tissues. Bacterial infection or 
pro-inflammatory cytokines such as TNF-α activate the Iκ B kinase (IKK) which phosphorylates the 
NFκ B repressor Iκ B, targeting it for ubiquitination and proteasomal degradation7. Free NFκ B dimers 
translocate to the nucleus where the p50 protein directly associates with the 5′ -GGGACTTTC-3′ con-
sensus DNA sequence in the promoters of NFκ B target genes initiating an inflammatory response8. We 
generated a FLuc/eGFP reporter lentivirus under the conditional control of 8x serial NFκ B binding 
sequences. We demonstrate the utility of resultant tissue specific NFκ B reporter rodents as a drug eval-
uation platform for the assessment of anti-inflammatory substances. Similarly, we show repression of 
NFκ B activity but activation of a similarly designed glucocorticoid receptor response element (GRRE) 
reporter by the corticosteroid analogue dexamethasone. Finally, to show activation of a further com-
monly investigated signaling pathway we show that liver specific TGF-β activated Smad2/3 reporter mice 
are responsive to a single intraperitoneal dose of the TGF-β superfamily ligand, Activin A.
Results
Generation of a library of lentivirus vectors containing transcription factor activated report-
ers. First we sought to generate a library of widely applicable TF activated reporter lentiviral con-
structs encompassing many of the commonly investigated signaling pathways in biomedical research. We 
constructed a parental lentiviral vector with a Gateway® acceptor site upstream of a minimal promoter 
driving a codon optimized, heat stabilized FLuc/eGFP bicistronic expression cassette (Supplementary 
Fig. 1). By de novo synthesizing serial repeats of known TF consensus sequences and rapid Gateway® 
cloning into the parental cassette we have designed and generated a preliminary library of 16 TF acti-
vated reporter lentiviral vectors. We transduced cell lines at a multiplicity of infection of 10 with these 
vectors and stimulated the reporters with appropriate pathway agonists/antagonists. All reporters showed 
significant specific responses which varied in time and amplitude depending on the reporter, cell line and 
agonist/antagonist (Fig. 1a). This was expected as biological responses will alter in length and magnitude 
as well as varying between cell types.
Administration of lentivirus containing NFκB reporter to rodents to examine feasibil-
ity of organ targeting, durability of expression, and LPS dose-responsiveness. Initial 
proof-of-concept in vivo experiments were designed to assess whether long-term biosensing of transcrip-
tion factor activity could be achieved in an organ or tissue-specific manner following neonatal lentivirus 
vector administration (Fig.  2). To assess optimal dose, NFκ B reporter lentiviral vectors pseudotyped 
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Figure 1. In vitro validation of a library of transcription factor activated lentiviral reporter vectors. 
Cells were transduced with the VSV-G pseudotyped lentiviral vectors at an MOI of 10 then incubated with 
the relevant agonists/inhibitors for the appropriate duration (Supplementary Table 2). (a) Each treatment 
induced a significant effect in cells containing the respective transcription factor response element between 
24 and 72 h post-treatment (n = 3–6, mean + /− SEM, comparison by Student’s t-test). (b) A list of 
transcription factors, agonist/inhibitors and cell types.
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with the wide tropism VSV-G envelope were injected intravenously into newborn (P0/1) outbred mice. 
We consistently used doses of ≈ 2 × 107 vp/mouse in all subsequent experiments, regardless of adminis-
tration route. Intravenous injection of VSV-G pseudotyped vector in neonates results in targeted trans-
duction of the liver as determined by ex vivo tissue luminometry (Supplementary Fig. 2). As predicted 
we observed a dose response in FLuc expression to LPS optimal at 1,200 ng/kg (Supplementary Fig. 3). 
We have endeavored to construct a method of data analysis which accommodates for sources of error 
and minimizes subjective interpretation. If data is presented as total bioluminescence (Supplementary 
Figure 4) there is variation in initial, baseline bioluminescence, which may be a consequence of genetic 
diversity (these are outbred mice) and differences in vector delivery and infection efficiency. Therefore we 
have calculated and presented all data as fold increase over baseline – Δ bioluminescence. To ensure this 
baseline is representative of true basal bioluminescence, we have derived the median of three consecutive 
images, taken on consecutive days where possible. Median, unlike mean, is a robust measure of central 
tendency and therefore would be unaffected by an outlier in the baseline triplet. Supplementary Figure 
4 reveals that total bioluminescence fell around fourfold from birth to around 40 days of life, then fell 
around 50% again over the ensuing 200 days. However, a fall in overall signal does not appear to correlate 
with diminished sensitivity, and a second dose of LPS induced a strong NFκ B response which was not 
significantly different from the response to the first LPS dose.
Liver and brain targeting. For evaluation of LPS-induced inflammation, the NFκ B reporter lentivi-
ral vector was administered by intravenous or intracranial injection to target the liver and brain, respec-
tively. Immunohistochemical staining for GFP in livers collected 24 hours after LPS stimulation revealed 
predominant expression in hepatocytes (Fig.  3a, blue arrows) although occasional staining of biliary 
epithelium and Kupffer cells was evident. Intracranial administration showed widespread transduction 
with GFP expression in cells predominantly displaying neuronal and occasional astrocyte morphology 
(Fig 3b, blue and red arrows, respectively). Bioluminescence persisted in all tissues targeted for at least 7 
months (data not shown). To determine the effect on reporter gene activity in individual animals, each 
data point was measured as a fold-change over the baseline. A single challenge with LPS induced marked 
up-regulation of luciferase activity in liver and brain within 24 hours, which returned to pre-challenge 
levels within 7 days (Fig. 3ci & ii; n = 8 per group, P < 0.01). Furthermore, we show that animals can be 
re-used in repeat experiments by re-administration of LPS 47 days after the first dose in liver specific 
NFκ B somatotransgenic mice. A second acute peak in luciferase activity was observed that was signifi-
cantly higher than the initial response (P< 0.01). Bioluminescence signal was detected in all treated mice 
for the duration of the experiment.
Lung targeting. Since vectors pseudotyped with the VSV-G protein transduce pulmonary airway 
epithelium poorly, we generated vectors pseudotyped with the baculovirus envelope glycoprotein, gp64, 
which mediates efficient epithelial transduction in neonatal lungs9. Lung-specific NFκ B reporter mice 
were generated by intranasal administration of the vector to newborn animals. LPS was then admin-
istered by nebulization to the adult mice. The minimal efficacious dose was determined by counting 
total leukocytes, neutrophils and eosinophils in bronchoalveolar lavage fluid (Supplementary Fig. 5). 
Figure 2. Schematic representation of the Somatotransgenic BLI methodology. Serial transcription factor 
binding sequences are de novo synthesized and inserted upstream of a minimal promoter driving a FLAG-
tagged firefly luciferase-2A-eGFP lentiviral expression cassette. High titer lentiviral preps are generated with 
tissue tropic pseudotyped envelope proteins. Lentivirus is administered to neonatal rodents by various routes 
and the degree of bioluminescence observed is proportional to the activation of the pathway controlled by 
the associated transcription factor.
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Optimized LPS nebulization induced a peak in pulmonary luciferase expression at 24 h, which returned 
to baseline within 48 h (Fig. 3d; n = 4, P < 0.01).
Confirmation of biosensor specificity. To confirm specificity of the biosensor response to NFκ B 
activation, we compared the effects of LPS on outbred and Tlr4−/− mice. Animals were injected intrave-
nously with vector encoding luciferase/eGFP under control of either the constitutively active promoter 
derived from spleen focus-forming virus (SFFV), or the NFκ B-responsive transcription element. LPS 




Figure 3. Lipopolysaccharide (LPS)-mediated induction of NFκB-activated reporter cassette in targeted 
organs of reporter mice. Preparations of NFκ B reporter lentiviral vector pseudotyped with VSV-G were 
administered to newborn outbred mice by intravenous (n = 9) or intracranial (n = 9) injection to target liver 
and brain, respectively. After establishing a baseline at 34 days, reporter mice were challenged with LPS and 
BLI measured continually thereafter. After 24 h mice receiving intravenous and intracranial injections were 
sacrificed and GFP immunohistochemistry performed on (a) liver and (b) brain sections, respectively. Liver 
staining was found predominantly in hepatocytes (a, blue arrows); Brain GFP expression was seen mainly in 
cells of neuronal (b, blue arrows) and astrocyte (b, red arrows) morphology. Photon emission was restricted 
to (ci, image) liver and (cii, image) brain, respectively. Both (ci, graph) liver and (cii, graph) brain showed 
acute early responses to LPS stimulation. Baseline BLI was re-established in liver specific animals and were 
re-stimulated at 83 days and imaged over the same timeframe. The NFκ B reporter lentiviral vector was 
pseudotyped with gp64 envelope for (d) nasal administration to the lung airway epithelium of neonatal 
mice. Adult mice were challenged with LPS at 48 days (n = 4) and BLI quantified continually thereafter. 
Lung targeted somatotransgenic animals showed an acute response to LPS (*P < 0.01, repeated measures 
ANOVA). Images are presented as captured at the time of peak bioluminescence for each experiment.
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n = 7–21; one-way ANOVA P < 0.01), compared to no response in Tlr4−/− mice. This demonstrates that, 
as with our in vitro validation, the NFκ B biosensor was specific for TLR4-dependent induction of NFκ B 
by LPS. For experiments like this, with two or more treatment groups possessing the same biosensor, we 
derived an area under curve for each group. We felt this was more representative of total transcription 
factor activity over the duration of the experiment and provided a more objective method of analysis 
for further experiments. Therefore we have presented a kinetic profile of bioluminescence as well as area 
under curve. Overall, absence of an effect in either strain of mice treated with the vector encoding the 
SFFV promoter indicates that the NFκ B binding sequences alone, not the lentiviral vector backbone, 
conferred sensitivity to LPS-induced activation of transcription by NFκ B.
To evaluate the transferability of the somatotransgenic approach to alternative rodent species, we 
targeted the livers of Sprague-Dawley rats using the same NFκ B biosensing lentiviral vector (Fig. 5a,b; 
n = 7). Challenge with LPS induced a significant increase in BLI, which was similar to that seen in mice 
(P < 0.01).
Using light producing somatic transgenic mice for in vivo analysis of drug efficacy. Liver- 
specific NFκ B reporter mice were used to assess inhibition of pro-inflammatory transcriptional acti-
vation by an anti-inflammatory drug. The glucocorticoid analogue dexamethasone is known to inhibit 
NFκ B activity through multiple direct and indirect mechanisms10. Mice received LPS with or without 
dexamethasone and LPS induced an NFκ B-mediated up-regulation in luciferase expression, which was 
completely ablated by dexamethasone (Fig. 6a; n = 8 per group; one way ANOVA P < 0.05). This valida-
tion of a known anti-inflammatory drug proves that this protocol may be employed for drug evaluation 
using real time analysis in vivo. As well as inhibiting NFκ B-mediated inflammation, dexamethasone will 
also upregulate the glucocorticoid receptor (GR) response resulting in the activation of gene promoters 
containing GRRE11. We generated liver-targeted GR reporter mice and subjected them to intra-peritoneal 
injection of dexamethasone. In this case, we observed a significant upregulation of FLuc expression 
for two days following dexamethasone administration (Fig. 6b; n = 8 & 7; ANOVA P < 0.05). Together 
these data show that we are able to use multiple transcription factor-activated reporters to interrogate 
dual activity of a single drug. Finally, we sought to show direct downstream transcription factor activity 
after applying a cytokine in vivo. We generated liver-targeted Smad2/3 reporter somatotransgenic mice 
as a biosensor for the TGF-β family member Activin A. Smad2/3 somatotransgenic mice received an 
intraperitoneal injection of Activin A whereas control mice received LPS as a non-activating control. An 
acute BLI response after Activin A but not LPS demonstrated Smad2/3-specific biological sensor activity 
and no cross-activation (Fig. 6c; n = 13 per group; one-way ANOVA P < 0.01).
In conclusion, these experiments describe generation of a library of transcription factor-activated 
reporters, using a technology which can be used easily and inexpensively to vectorize any desirable 































Figure 4. NFκB reporter activation by LPS is TLR4 dependent in liver targeted somatotransgenic mice. 
Preparations of NFκ B reporter lentiviral vector pseudotyped with VSV-G were injected intravenously into 
newborn outbred mice to achieve liver-targeted expression (a) Liver-specific NFκ B pathway activity was 
determined by LPS challenge in outbred NFκ B (n= 21) and constitutively active SFFV reporter (n = 7) 
mice versus Tlr4−/− NFκ B (n = 9) and SFFV (n = 7) reporter mice. (b) Only wild-type NFκ B reporter mice 
showed significant increase in luciferase activity (*P< 0.01, repeated measures ANOVA).
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vector by the appropriate route can target liver, brain and lung. This is achieved in outbred mice, knock-
out mice, and rats. Using NFκ B as an example, we observe that the biosensor acts in a dose-dependent 
manner to the LPS agonist, and that it is specific to the toll-like receptor 4 signaling pathway. Finally, 
we have been able to show utility, in the liver, in assessing drug efficacy, using dexamethasone, and have 
shown that an additional biosensor, Smad2/3, responds to the ligand Activin A.
Discussion
Luciferase assay is established as the predominant modality of transcriptional activity studies in vitro and 
now luciferase BLI is becoming more commonplace in living animals. However, continual BLI in rodents 
has been employed largely to quantify bacterial colonization12 and engraftment of cancer cells13 and stem 
cells14. Most recently, germline LPT mice have been generated by inserting the luciferase gene down-
stream of an endogenous gene promoter to act as a quantifiable surrogate for gene expression in living 
animals. Since Contag et al.15 first described germline LPT mice, the diverse utility has been evidenced 
in studies of development16, normal physiology3 and disease pathogenesis17 including oncogenesis and 
metastasis2,4. A further technological iteration has been the genomic insertion of conditional expression 
cassettes where luciferase is activated by serial transcription factor binding sequences driving a minimal 
promoter18. In this context, TF activity can thus be discriminated from promoter activity.
To date there have been over twenty LPT mice described in the literature, ten of which contain tran-
scription factor activated synthetic promoters. Since they possess an integrated luciferase sensor cassette, 
production of mice for experiments requires nothing more than breeding, rather than the technique 
described herein, of neonatal vector injection. However, the initial generation of transgenics is extremely 
time consuming and the lines are costly to produce and maintain; it is estimated that from transfection 
of ES cells to the first litter of homozygous mice takes approximately one year at a cost of approximately 
$12,00019. Targeted knock-in transgenics may also be compromised by off-target activity20,21. For exam-
ple, Ciana et al. showed that an estrogen receptor-responsive light producing transgenic was subject to 
both variation in tissue activity and agonist activation in F1 progeny22. This variation could be caused by 
positional effects with the inserted transgene, also reported by Zinn et al.23. Avoiding this effect would 
require extensive analysis of F1 progeny and therefore adds to the time and cost of developing the animal 
model.
We have developed an alternative approach that enables rapid generation of mice with tissue-restricted 
bioluminescent reporter activity. The combination of lentiviral pseudotyping and neonatal administra-
tion to target specific tissues allows for the generation of a large variety of somatic transgenic rodents. 
Production is rapid and cost effective compared with generation of germline transgenic rodents. 
There are several previous studies describing production of somatic, transgenic, light emitting mice 
by adult gene delivery. For example hydrodynamic plasmid injection has been used to monitor activ-
ity of the hepcidin promoter24; a separate study described intramyocardial injection of plasmid con-
taining a heart-specific promoter25. Intra-tumoral injection of adenovirus vector was used to measure 
Figure 5. Lipopolysaccharide (LPS)-mediated induction of liver specific NFκB-reporter rats. Liver 
biosensing rats were generated by injection of VSV-G-pseudotyped NFκ B reporter lentivirus (titer 
5 × 109 vp/ml) intravenously into the superficial temporal vein of newborn Sprague-Dawley rats (n = 6). 50 μ l 
LPS (125 μ g/kg) was administered by intra-peritoneal injection at 33 days and BLI carried out at 12, 24, 48 
and 168 h. (a) As in mice, expression was localized to the liver and (b) there was a significant acute early 
response in luciferase expression, peaking 12 hours after LPS administration (*P < 0.01, repeated measures 
ANOVA).
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alpha-fetoprotein-promoter/enhancer activity26. Adenovirus vector was injected into distinct CNS nuclei 
to measure NFκ B activity27. However we28 and others29 have demonstrated that systemic vector deliv-
ery can provoke an immune response which can eliminate transduced cells whereas neonatal delivery 
can induce CD4+ CD25+ T cell-mediated tolerance to the transgenic protein30. Specific administration 
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Figure 6. Reporter mice as an in vivo drug evaluation platform using continued BLI imaging. For all 
three experiments, outbred mice received neonatal intravenous injection of ≈ 2 × 107 vp/mouse of VSV-G 
pseudotyped vector to achieve liver-targeted expression of different reporters. (a) NFκ B reporter mice were 
treated with either dexamethasone (113 μ g/mouse, n = 8) or vehicle (n = 8) at − 2 h and concomitantly 
with LPS challenge. There was a significant suppression of BLI in the dexamethasone treatment group 
(*P = 0.047). (b) GRRE reporter mice were treated with either dexamethasone (450 μ g/mouse, n = 8) 
or vehicle (n = 8) and subjected to BLI over 14 days. There was a significant upregulation of BLI in the 
dexamethasone treatment group (*P < 0.05). (c) Smad2/3 reporter mice received an i.p. injection of Activin 
A. Control mice received i.p. LPS. An acute Smad2/3-specific BLI response was observed after Activin A but 
not LPS (n = 13 each group; P < 0.01, Student’s t-test).
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transgenic rodents which may occasionally suffer from positional effects exerted by regulatory elements 
proximal to the integration site, retroviral vectors integrate in a semi-random pattern therefore overall 
expression is unlikely to be influenced by any single local enhancer or repressor.
We chose to concentrate our evaluation of this technology on an NFκ B reporter construct for two 
reasons: Firstly, NFκ B is a mediator of the early inflammatory response and hence its activity and modu-
lation is important in the pathogenesis of many disease states and is a target for anti-inflammatory drugs. 
Secondly, a light-emitting germline NFκ B transgenic mouse model is established33–35 but not widely used 
because of problems associated with substantial multi-tissue background signal. NFκ B activity plays 
multiple roles in proliferation, apoptosis and stem cell differentiation8 within normal tissue homeostasis. 
Consequently, off-target bioluminescence activity renders BLI of visceral tissues practically impossible 
in germline NFκ B transgenic models.
We generated liver, brain and lung targeted NFκ B reporter mice and showed repeated acute responses 
to LPS. In the liver we observed a greater response to the second LPS administration compared with 
the first. This contradicts many studies showing that repeated LPS dosing induces tolerance. However, 
many of these studies have used readouts downstream of the primary signaling pathways (e.g. leukocyte 
infiltration, nitric oxide production) whereas here, we have been uniquely able to quantitate NFκ B acti-
vation. Other rodent models are used in biomedical research and we have shown that this technology 
can be also be applied across any species that is compatible with in vivo bioimaging by producing LPS 
responsive liver specific NFκ B somatotransgenic rats. A further substantial advantage of somatotrans-
genic technology is that it can be conveniently layered upon existing transgenic mouse strains. We took 
advantage of this to prove that the NFκ B- reporter was stimulated directly via LPS/TLR4-mediated 
NFκ B signaling. Ultrapure LPS-induced BLI responses were completely ablated in Tlr4−/− mice com-
pared to wild-type controls or a promoter not influenced by NFκ B (SFFV). This proves at a cellular 
level that NFκ B-mediated expression of luciferase is regulated through TLR4. Although this data is 
proof-of-principle it shows that somatotransgenic BLI can potentially be used to verify the downstream 
function of any protein in knockout mice where there is downstream modulation of transcription factor 
activity.
A widely applicable utility of this technology is in drug efficacy studies. We used liver targeted NFκ B 
reporter mice to show that intraperitoneal administration of the anti-inflammatory glucocorticoid ana-
logue dexamethasone, prior to giving LPS, completely ablated the temporal NFκ B BLI response. This 
shows that such an in vivo platform could be used in the early stage evaluation of potentially therapeutic 
compounds. This is useful not only in the study of inflammation but in analysis of any drug that is 
designed against a protein target whose activation or repression results in modulation of transcription 
factor activity. Finally, we sought to show that a defined TF activated reporter was upregulated directly 
by a cytokine in vivo. We achieved this by generating a Smad2/3 activated reporter which is responsive 
to TGF-β family members. Liver specific Smad2/3 somatotransgenic mice showed a significant response 
to a single intraperitoneal dose of Activin A compared to no response to LPS as a non-activating con-
trol. This shows that in vivo TF-activated reporters are faithful to predictive biological agonists. In this 
study we have shown proof of principle for bioluminescence imaging of transcriptional activation in 
three organs – liver, lung and brain. However, the technology should be applicable to any tissue or organ 
which can be transduced by lentivirus vector. This, in turn, depends upon, and is restricted by, route of 
administration and the vector pseudotype.
The 3Rs principles are to reduce, refine or replace the use of animals in biomedical research, wherever 
possible. BLI using germline or somatotransgenic mice substantially reduces the number of animals nec-
essary for longitudinal studies of gene expression compared to conventional endpoint analyses as well as 
increasing quality by maintaining continuity within experiments. In summary we have developed a new 
methodology for rapidly generating tissue-specific BLI rodent models for use in disease pathogenesis 
and drug efficacy studies. Somatotransgenic BLI can be applied to the study of a wide array of signaling 
networks. We have generated and in vitro validated an initial library of 16 lentiviral reporter cassettes 
suitable for interrogating transcription factor activity in proof of principle studies using NFκ B, GR and 
Smad2/3 reporters. Using this new technology, kinetic profiles of signaling pathways can be obtained 
using smaller groups of animals, at a lower cost and in a shorter period of time.
Methods
Construction of lentiviral reporter vectors. Triple overlap-extension PCR was performed using 
Phusion high-fidelity polymerase (NEB) and primer sets to amplify 3xFLAG, FLuc, and 2A-eGFP. 2A is 
the Foot and Mouth Disease Virus 2A cleavage peptide sequence and serves as a polycistronic linker, as 
previously described36. The upstream primer (F1) was engineered to contain a unique BamHI restric-
tion site, while the downstream primer (R3) contained a unique MluI site. A single in-frame cistron 
was generated by overlap-extension secondary PCR using the three primary PCR products as template 
and 3xFLAG (F1) and 2A-eGFP (R3) primers for amplification. This produced the BamHI-FLAG-Luc-
2A-eGFP-MluI fragment which was sub-cloned into an intermediary plasmid using the BamHI/MluI sites 
and then shuttled into our parental pLNT-Gateway-MCS vector using SalI/MluI into XhoI/MluI to create 
pLNT-Gateway-JDG (Supplementary Fig. 1). To shuttle transcription factor activated promoters into 
the Gateway® recombination site we first cloned the adenoviral E1a minimal promoter sequence (MP) 
into the Gateway® shuttle vector pENTR-1A (Invitrogen) by hybridizing overlapping oligonucleotides 
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MP (F & R) both containing terminal XhoI sites. This product was then ligated into the unique XhoI 
site of pENTR-1A and correctly oriented clones confirmed by sequencing. This plasmid (pENTR-MP) 
acted as an intermediary shuttle vector into which serial transcription factor binding elements (TFBE) 
were cloned (Table 1). TFBE were de novo synthesized by Aldevron (Fargo, ND, USA) and ligated into 
pENTR-MP using unique BamHI/EcoRI sites. Sequence verified TFBE-MP sequences were recombined 
into pLNT-Gateway-JDG using Gateway® cloning technology (Invitrogen) as per manufacturer’s instruc-
tions.
Lentivirus production and titering. 293T viral producer cells were seeded overnight at 2 × 107 cells 
per T175  cm2 flask and transfected using 50 μ g pLNT-TFBE-JDG, 17.5 μ g pMD.G2 (VSV-G envelope 
plasmid), and 32.5 μ g pCMVΔ R8.74 (gag-pol packaging plasmid) pre-complexed with 1 μ l polyethylen-
imine (10 mM) (Sigma-Aldrich) in OptiMEM for 3 h. Transfection media was replaced with complete 
DMEM and viral supernatant collected at 48 and 72 hours, filter sterilized (0.22 μ M), and concentrated by 
overnight low-g centrifugation. Pellets were resuspended in OptiMEM and stored at − 80 °C. All viruses 
were titered using a p24 assay (Zeptometrix, Buffalo, NY, USA) as per manufacturer’s instructions.
In vitro validation of reporter gene activity. 293T, HeLa and NIH3T3 cells were cultured in DMEM 
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin (Sigma), 2 mM L-glutamine and 
1x non-essential amino acids. HepaRG cells were cultured in William’s E media containing Glutamax 
and sodium pyruvate supplemented with 10% FBS, 1% Pen/Strep, 1x non-essential amino acids, 4 μ g/ml 
human recombinant insulin zinc solution, and 50 μ M hydrocortisone. All reagents were sourced from 
Life Technologies.
Lentiviral expression constructs were initially validated using an SFFV constitutive promoter driving 
expression of the firefly luciferase-eGFP bicistronic reporter. Efficient 2A cleavage was confirmed by 
western blot for FLAG (Sigma-Aldrich F7425; 1:1,000) and eGFP (AbCam Cat: Ab290; 1:10,000) using 
standard methodologies and Fluorescence Activated Cell Sorting using a FACS Calibur flow cytometer, 
data capture using Cell Quest and data analysis using FlowJo v7.6.4 software (data not shown).
For the validation of transcription factor activated gene expression in vitro (except Notch), we trans-
duced cells with VSV-G pseudotyped lentivirus reporters at an MOI of 10 then applied small molecule 
or growth factor agonists or inhibitors as detailed in Fig. 1b and Supplementary Table 2. For analysis of 
the Notch reporter we transduced the trophoblast isolated cell line, SGHPL5, then mixed with HEK93T 
cells transduced with Jagged-1 expressing lentivirus or empty vector and co-cultured for 72 h prior to 
analysis.
Gene activation was quantified by luciferase luminometry on cell lysates as follows: 20 μ l assay buffer 
(25 mM Tris phosphate pH 7.8, 1mM DTT, 1 mM EDTA, 1% Triton X-100, 8 mM MgCl2, 3 ml glyc-
erol, 1.25 mM rATP, 0.5% BSA) was added to 20 μ l cell extract. Luciferin (Gold Biotechnology, MO, 
USA) was added to a final concentration of 1.5 mM and luminescence measured using the POLARstar 
Omega microplate reader (BMG Labtech). Analysis performed using MARS data analysis software (BMG 
Transcription 
factor Sequence
NFκ B (GGGACTTTCC) × 8
SMAD2/3 (AGCCAGACA) × 8
SMAD1/5/8 (CGCGGCGCCAGCCTGACAGCCCG) × 6
HIF (TACGTGCT) × 8
TCF/LEF (AGATCAAAGGGGGTA) × 8
ER (GTCAGGTCACAGTGACCTGAT) × 4
p53 (AGACATGTCCAGACATGTCCGAACATGTCCCAACATGTTGT) × 4
AP-1 (TGAGTCAG) × 8
FOXO1 (GATCAAGTAAACAACTATGTAAACAA) × 4
STAT3 (GTCGACATTTCCCGTAAATCGTCGA) × 4
GLI (GACCACCCAC) × 8
NRF2 (TCACAGTGACTCAGCAAAATT) × 8
AhR (TGAGTTCTCACGCTAGCAGAT) × 8
NFAT (GGAGGAAAAACTGTTTCATACAGAAGGCGT) × 4
GR (GGTACATTTTGTTCT) × 8
Notch (CGTGGGAA) × 8
Table 1.  List of transcription factor binding element sequences.
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Labtech). Relative light units were normalized relative to total protein as determined by Bradford assay 
(BioRad) using manufacturer’s instructions.
Animal procedures. Unless otherwise stated, outbred CD1 mice (Charles River) were time mated to 
produce neonatal animals. At postnatal day 1, neonates were briefly anesthetized (on ice) and lentivirus 
injected by the appropriate route: Intravenous (via the superficial temporal vein); 20 μ l, Intracranial; 
5 μ l. Intranasal insufflation was achieved by restraining the neonate with mouth closed while 10 μ l of 
vector was placed on the nostrils. Neonatal outbred Sprague-Dawley rats (Charles River) received 50 μ l 
of intravenous lentivirus. Mice deficient in the toll-like receptor 4 (TLR4−/−) were obtained from the 
Swiss Immunological Mouse Repository (SwImMR) and outbred onto the CD1 background. All experi-
ments were performed in accordance with relevant guidelines and regulations: Experiments were carried 
out under United Kingdom Home Office regulations and approved by the ethical review committees of 
Imperial College London and University College London.
Bioluminescence imaging. Unless otherwise stated, animals were anesthetized with isoflurane 
(Abbott Laboratories), injected i.p. with firefly D-luciferin (15 mg/ml in PBS; Gold Biotechnology) and 
imaged 5 min later with a cooled charge-coupled device (CCD) camera (IVIS; PerkinElmer). Luciferin 
dose was 150 mg/kg; volume varied with age/size of animal, for example, adult mice were given 300 μ l. 
Grey-scale photographs were acquired with a 24-cm field of view and then a bioluminescence image was 
obtained using a binning (resolution) factor of 4, a 1.2/f stop and open filter. Regions of interest (ROIs) 
were defined manually using a standard area for each organ under investigation. Signal intensities were 
calculated with Living Image software (Perkin Elmer) and expressed as photons per second per cm2 
per steradian. Where possible, BLI was carried out in adult reporter rodents on three consecutive days 
to establish a robust median baseline; subsequent data points were expressed as fold-change over this 
internal standard for each individual animal.
In vivo agonist activation. LPS was given i.p., at a dose of 30 μ g/mouse or 18.75 μ g/rat. For NFκ B 
BLI (Fig. 5a), dexamethasone was given i.p. 2 hours before and concomitantly with LPS and luciferin, at 
a dose of 113 μ g/mouse. For GRRE BLI (Fig. 5b) a dose of 450 μ g/mouse dexamethasone was injected. 
Activin A was injected i.p. at a dose of 25 μ g/mouse.
Immunohistochemistry. Brain was processed as previously described37. Whole brain was fixed in 4% 
paraformaldehyde. The brains were cryoprotected in 30% sucrose in 50 mM TBS prior to cryosectioning 
at 40-μ m sections using a Microm freezing microtome (Carl Zeiss, Welwyn Garden City, UK). eGFP 
expression was detected by immunohistochemical staining of the sections. Endogenous peroxidase activ-
ity in the sections was blocked by incubation in 1% H2O2 in TBS solution for 30 min. The sections were 
then rinsed three times in TBS before blocking of non-specific immunoglobulin binding by incubating 
sections for 30 min in a solution of 15% normal goat serum (NGS) in TBS-T (TBS solution containing 
0.3% Triton X-100). Sections were then incubated overnight at 4 °C in rabbit anti-GFP (1:10 000; Abcam, 
Cambridge, UK) in TBS-T/ 10% NGS. The following day, the sections were rinsed in TBS and incubated 
for 2 h in goat ant-rabbit IgG diluted in TBS-T/10% NGS, rinsed again in TBS and incubated for 2 h in 
a 1:1000 solution of Vectastain avidin-biotin solution (ABC; Vector Labs, UK) in TBS prepared 30 min 
before use. Subsequently, sections were rinsed again and incubated in a freshly made and filtered 0.05% 
solution of DAB containing 0.01% H2O2 to visualize GFP immunoreactivity. The staining reaction was 
stopped by rinsing in ice-cold TBS. Stained sections were subsequently mounted onto chrome gelatine 
coated Superfrost-plus slides (VWR, Poole, UK) and left to dry overnight. Sections were then dehydrated 
in a series of rising concentrations of industrial methylated spirits, cleared in xylene for 20 min and 
coverslipped using DPX mounting medium (VWR). Liver tissue was fixed in 25% formalin overnight, 
transferred to 70% ethanol, and processed into paraffin. eGFP immunohistochemistry was performed on 
mounted, rather than free-floating sections.
Statistical analysis. Statistical analysis on in vitro vector analysis data was performed using an 
unpaired Student’s one-tailed t-test. All data are expressed as mean values ± SEM, with each sample 
being measured at least in triplicate. For in vivo data, repeated measurements following agonist admin-
istration were analyzed with repeated measures analysis of variance with significance level of P < 0.01. 
Area under curve data for experiments with two groups were analyzed by Student’s one-tailed t-test. For 
areas under curve derived from two or more groups, one-way analysis of variance with Newman-Keuls 
post-hoc multiple comparison test was performed. For lung leukocyte analysis, one-way ANOVA with 
Dunn’s post-hoc test against vehicle control was performed.
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